Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Deciphera Pharmaceuticals, Inc. DCPH
$13.63
-$0.12 (-0.87%)
На 18:00, 12 мая 2023
+51.65%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1072646036.00000000
-
week52high
22.76
-
week52low
9.08
-
Revenue
134036000
-
P/E TTM
-6466
-
Beta
0.67820000
-
EPS
-2.28000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 12:30
Описание компании
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 05 авг 2022 г. |
| JMP Securities | Market Outperform | Market Perform | 05 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 05 авг 2022 г. |
| Barclays | Underweight | Equal-Weight | 28 февр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 01 дек 2021 г. |
| SVB Leerink | Outperform | Outperform | 12 сент 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 12 сент 2022 г. |
| Cowen & Co. | Outperform | 29 авг 2022 г. | |
| Stifel | Hold | Hold | 27 сент 2022 г. |
| JonesTrading | Hold | Sell | 06 янв 2023 г. |
| SVB Leerink | Outperform | Outperform | 04 янв 2023 г. |
| Guggenheim | Buy | Neutral | 04 янв 2023 г. |
| Barclays | Underweight | Underweight | 04 янв 2023 г. |
| Cowen & Co. | Outperform | Outperform | 25 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Brightstar Associates LLC | A | 19718014 | 1666666 | 24 янв 2023 г. |
| Flynn Daniel Lee | D | 43695 | 2403 | 17 янв 2023 г. |
| Friedman Franklin Stuart | A | 3269 | 3269 | 17 янв 2023 г. |
| Kelley Susan L. | A | 3269 | 3269 | 17 янв 2023 г. |
| Squarer Ron | A | 3269 | 3269 | 17 янв 2023 г. |
| Kelly Thomas Patrick | D | 43677 | 2403 | 17 янв 2023 г. |
| Walsh Dennis Leo | A | 3269 | 3269 | 17 янв 2023 г. |
| Martin Daniel C. | D | 48389 | 1603 | 17 янв 2023 г. |
| Allen Patricia L | A | 3269 | 3269 | 17 янв 2023 г. |
| Sherman Matthew L | D | 72628 | 2403 | 17 янв 2023 г. |
Новостная лента
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
Business Wire
08 мая 2023 г. в 07:00
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 2:30 PM ET in New York, NY. A live webcast of the fireside chat will be available on the “Events and Pre.
Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2023 Earnings Call Transcript
Seeking Alpha
07 мая 2023 г. в 04:58
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Jen Larson - Senior Vice President-Finance and Investor Relations Steve Hoerter - President and Chief Executive Officer Matt Sherman - Chief Medical Officer Dan Martin - Chief Commercial Officer Margarida Duarte - Head of International Tucker Kelly - Chief Financial Officer Conference Call Participants Tyler Van Buren - Cowen Bradley Canino - Stifel Reni Benjamin - JMP Securities Andrew Berens - SVB Securities Operator Good morning, everyone, and welcome to Deciphera Pharmaceuticals First Quarter 2023 Financial Results Conference Call. Later, we will conduct a question-and-answer session.
Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss
Zacks Investment Research
04 мая 2023 г. в 06:53
Deciphera Pharmaceuticals (DCPH) reports mixed first-quarter 2023 results as its earnings are in line with the Zacks Consensus Estimate, while revenues miss the same.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
03 мая 2023 г. в 09:55
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.80 per share a year ago.
Deciphera Pharmaceuticals: In The Middle Of A Major Comeback (Upgrade)
Seeking Alpha
25 мар 2023 г. в 08:00
Last year, Deciphera Pharmaceuticals, Inc. was almost destroyed by a trial failure. This year, Deciphera Pharmaceuticals has demonstrated huge benefit in a subpopulation, and also progressed the rest of its pipeline.